The middle layer of the eye, known as the uvea, becomes inflamed when someone has eye inflammation or uveitis.

An investigational Janus kinase 1 (JAK1) preferential inhibitor reduced the risk of treatment failure among patients with active noninfectious uveitis, the phase II randomized HUMBOLDT trial showed.

Higher anti-drug antibody levels were associated with an increased risk for tumor necrosis factor inhibitor treatment failure in patients with noninfectious uveitis who received adalimumab, according ...